Why genetic data requires a different security posture
Most clinical records carry information about one patient. A BRCA1 or BRCA2 gene change result carries information that matters to that patient's blood relatives - sometimes across three generations. That single result can affect insurance eligibility, family planning choices, and surgical decisions for people who have never visited your clinic.
That difference - one test result affecting multiple people - is why genetic data needs special security. A breach of a standard cancer record harms one patient. A breach of a BRCA result can affect an entire family's health information.
Women with a BRCA1 gene change face a 39% to 44% lifetime risk of ovarian cancer, compared with roughly 1.4% in the general population. Women with a BRCA2 change face an 11% to 17% risk. These numbers come from a review of management data published via PMC (NIH). BRCA gene changes account for roughly 18% to 20% of ovarian cancers, according to a clinical analysis available through PMC (NIH). The health stakes are high, and the data that shapes decisions needs careful handling.
Testing rates still leave gaps
Even with established clinical guidelines, many patients with ovarian cancer are not receiving BRCA tests in formats that can be retrieved from their records. A nationwide study found that only 50.2% of advanced-stage ovarian cancer patients completed tumor testing - and BRCA1/2 gene changes were found in 14.7% of those tested. That study is accessible via PMC (NIH).
Two problems drive those gaps. First, the test result comes from an outside lab as a PDF or report, usually landing in an inbox rather than as a field in the clinical record. Second, even when the result is filed, the next steps - telling family members, scheduling follow-up visits, flagging treatment options - are often tracked by hand or not tracked at all.
A platform that pulls BRCA result data automatically from incoming lab documents and links it to workflow tasks closes both gaps. For more on how AI-driven document extraction works in practice, see our article on turning lab PDFs into structured patient insights.
The cascade testing challenge
When an index patient tests positive for a BRCA gene change, clinical guidelines recommend offering testing to close relatives. In practice, that recommendation is hard to carry out. Research published in Scientific Reports (Nature) found that while most index patients said they told at least one relative, actual testing among invited relatives reached only 47.5%. A separate analysis reported that only 32.3% of families with gene changes in cancer susceptibility genes had completed cascade testing at all, with data accessible at PMC (NIH).
A study published in JCO Precision Oncology (ASCO) examining how clinicians and patients talk about cascade testing found that genetic counselors were most active in encouraging family talks - involved in 71.5% of cases - while oncologists were cited in 33.4% of cases. That difference highlights a workflow gap: the clinician most likely to start cascade talks is often not the same person treating the patient long-term.
For a clinic running an active hereditary cancer program, those numbers have a direct impact. Every untested at-risk relative is a possible missed high-risk patient. Tracking who has been notified, who has agreed to testing, and who has not responded requires a workflow tool that standard EHR systems were not built to provide.
Cascade tracking also raises a specific data question: how does a clinic tell a patient's sibling about a BRCA result in a HIPAA-safe way when that sibling is not yet a patient in the system? The answer involves consent-aware secure messaging and detailed audit records - not unsecured email. For a related look at managing information between multiple providers in oncology, see our piece on dual-provider coordination in integrative breast cancer care.
Where security gaps occur in BRCA workflows
Genetic data in oncology clinics typically moves through four touchpoints where a breach is most likely. Identifying each one is the first step toward fixing it.
- Report ingestion. BRCA reports from commercial labs arrive via fax, secure email, or HL7 message. Fax-to-PDF workflows leave reports sitting in shared inboxes or unindexed folders. Without ingestion controls, the report may not be encrypted at rest, may lack an audit trail, and may be visible to staff with no clinical reason to access it.
- Annotation and documentation. Clinicians often record BRCA findings in free-text notes. Free-text is harder to remove personal information from, harder to track, and cannot be searched across a patient population. Structured data fields with role-based access controls are safer and more useful.
- Cascade communications. Notification letters to relatives, referral letters to genetic counselors, and result-sharing with other doctors all create copies of the genetic result outside the primary record. Each copy is a possible leak point if it travels without encryption.
- Interoperability exports. When a patient moves to another clinic, genetic data often goes along as part of a bulk record export. Without selective controls, a full-record transfer may include family history and pedigree data that was not approved for sharing with the new clinic.
The regulatory context: HIPAA and genetic information
Under the HIPAA Omnibus Rule, genetic information is classified as protected health information (PHI). The Genetic Information Nondiscrimination Act (GINA) prohibits health insurers from using genetic data to make coverage decisions. That legal framework sets a minimum for how genetic records must be handled - but many clinics are operating at that minimum rather than above it.
HHS published a proposed update to the HIPAA Security Rule in January 2025. The proposal would eliminate the distinction between required and optional rules, making all of them mandatory with few exceptions. It would also require encryption of electronic PHI and multifactor authentication as standard controls rather than optional ones. A practical breakdown of what those changes mean for clinics is available from Healthcare IT News.
HIMSS has submitted formal comments on the proposed rule, calling for an approach that fits the reality of smaller clinics. Their position is summarized at HIMSS.org. Regardless of how the final rule is written, the direction is clear: encryption and multifactor authentication are moving from best practice to baseline requirement.
For a broader look at what security standards actually mean in practice for patient data, see our article on what hospital-grade security actually means for patient data.
What a HIPAA-ready platform provides for BRCA data
A platform built for hereditary cancer workflows needs to address the full data lifecycle, not just file storage.
At the storage layer, AES-256 encryption at rest is standard for genetic records. Backup copies - including disaster-recovery snapshots - need the same encryption level. Regional data hosting matters: clinics with patients from multiple jurisdictions need to know which country their data physically sits in, because genetic data may be subject to other rules in some places.
In transit, TLS 1.3 is the current minimum for all data moving between the clinic platform, lab interfaces, and patient applications. Older TLS versions have known weaknesses. Any platform that cannot confirm TLS 1.3 support should explain the gap before a contract is signed.
At the access layer, role-based permissions should limit BRCA gene data to credentialed clinical staff. Administrative billing users typically do not need access to the genetic part of a record. A platform that gives everyone access to all patient data creates unnecessary exposure that is hard to fix after the fact.
Audit trails need to be locked and timestamped. If a BRCA result is accessed, exported, changed, or deleted, that event should be logged with the user identity and should not be changed after the fact. For cascade tracking, the audit log should also show when a family notification was generated and whether a follow-up cascade result was later received and linked to the main patient's record.
Zero-retention AI matters here. If the platform uses AI to extract or summarize BRCA report data, that AI should not save patient genetic data between sessions. An inference engine that stores genetic data creates a retention risk that is hard to track and hard to fix after a breach.
Putting BRCA surveillance into practice within the clinic
Security controls protect the data. Workflow tools make the data useful.
A structured surveillance module should flag when a BRCA-positive patient has not had a follow-up visit within the right timeframe, and when close relatives identified as at-risk have not completed testing. Those flags should show up in the doctor's standard workflow - not require a manual database query that most clinicians will not run between appointments.
Treatment options based on BRCA status should reach the treating oncologist as a structured clinical prompt, not buried inside a lab report folder. The platform's job is to surface relevant data in the right place at the right time. Clinical decisions stay entirely with the doctor.
For programs that include genetic counseling alongside cancer care, a single-record approach keeps the genetic result accessible to both the oncologist and the counselor without creating duplicate copies of the gene data. That single-record principle is where care coordination and data security meet.